Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health (NYSE:HIMS) had its target price boosted by equities research analysts at Bank of America from $30.00 to $32.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price objective indicates a potential upside of 4.50% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the company. Truist Financial restated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, March 10th. Leerink Partners lifted their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday, March 9th. Finally, Citigroup upgraded Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price target for the company from $13.25 to $24.00 in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $32.53.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $30.62 on Friday. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $6.98 billion, a price-to-earnings ratio of 60.04, a PEG ratio of 2.67 and a beta of 2.32. The stock’s fifty day simple moving average is $20.98 and its 200 day simple moving average is $31.36. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.11 EPS. As a group, sell-side analysts forecast that Hims & Hers Health will post 0.61 earnings per share for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider owned 8,752 shares of the company’s stock, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 204,857 shares of company stock valued at $5,285,706 in the last three months. Company insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Pathway Capital Management LP acquired a new position in shares of Hims & Hers Health during the third quarter worth $6,766,000. Steadview Capital Management LLC increased its holdings in Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after purchasing an additional 311,845 shares during the period. Farallon Capital Management LLC increased its holdings in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. BIT Capital GmbH increased its holdings in Hims & Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. Finally, State of Michigan Retirement System increased its holdings in Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after purchasing an additional 678,600 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Lilly partnership — HIMS expanded its platform to let clinicians prescribe Eli Lilly GLP‑1 products (Zepbound, KwikPen, Foundayo) with fulfillment via LillyDirect, widening its weight‑management offering and creating a clearer prescription revenue path. Article Title
• Positive Sentiment: JPMorgan initiation — JPMorgan initiated coverage with an Overweight rating and $35 price target, framing the Novo Nordisk partnership and broader GLP‑1 access as a potential turning point; that institutional endorsement lifted sentiment. Article Title
• Positive Sentiment: Product expansion into women’s care — HIMS is scaling menopause/perimenopause offerings (including estrogen patches) and boosting peptide capabilities, which broadens recurring‑care revenue streams beyond legacy DTC categories. Article Title
• Neutral Sentiment: Regulatory tailwind but with open questions — The FDA scheduled a July compounding advisory committee meeting on certain peptides; the market views this as validating peptide opportunity but outcome/timing remain uncertain. Article Title
• Neutral Sentiment: Analyst/target moves — Bank of America raised its target to $32 (Neutral) and several other shops have adjusted coverage; upgrades add support but consensus remains mixed, so analyst activity amplifies swings rather than resolving execution risk. Article Title
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders sold shares under Rule 10b5‑1 plans (SEC filings), which can sap near‑term sentiment despite being pre‑arranged. Article Title
• Negative Sentiment: Competitive pressure — Amazon’s entry into GLP‑1/weight‑loss programs and other deep‑pocket competitors raise concerns about margin pressure and share erosion in a key growth category. Article Title

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.